TIBBIY XIZMATLAR KO‘RSATISHDA MANFAATLAR TO‘QNASHUVI: HUQUQIY TARTIBGA SOLISH MUAMMOLARI
Kalit so‘zlar
Как цитировать
Abstrakt
Maqolada tibbiy xizmatlar ko‘rsatishda manfaatlar to‘qnashuvining yuzaga kelish sabablari, namoyon bo‘lish shakllari va huquqiy tartibga solish muammolari tahlil qilinadi. Shifokor, tibbiyot muassasasi, farmatsevtika kompaniyalari, diagnostika markazlari hamda sug‘urta tashkilotlari o‘rtasidagi moliyaviy yoki tashkiliy aloqalar bemor manfaatlari, tibbiy yordam sifati va kasbiy xolislikka salbiy ta’sir ko‘rsatishi mumkinligi asoslab beriladi. Mazkur maqolada tibbiy xizmatlar ko‘rsatish jarayonida manfaatlar to‘qnashuvining huquqiy va etik mohiyati tahlil qilinadi. Unda shifokor, tibbiyot muassasasi hamda farmatsevtika kompaniyalari o‘rtasidagi moliyaviy, tashkiliy yoki shaxsiy manfaatdorlik bemorning sifatli, xolis va xavfsiz tibbiy yordam olish huquqiga qanday ta’sir ko‘rsatishi yoritiladi. Maqolada manfaatlar to‘qnashuvining asosiy elementlari – asosiy manfaat, ikkilamchi manfaat va ularning o‘zaro ziddiyati ilmiy-nazariy jihatdan ochib berilgan. Shuningdek, dori vositalarini targ‘ib qilish, shifokorlarga sovg‘alar berish, homiylik va farmatsevtika savdo vakillari bilan munosabatlarning tibbiy qarorlar mustaqilligiga ta’siri xorijiy tajriba asosida tahlil qilingan. Maqolada O‘zbekiston qonunchiligida manfaatlar to‘qnashuvini tartibga solishning mavjud huquqiy asoslari ko‘rib chiqilib, ushbu sohada manfaatlarni oshkor qilish, ichki nazorat va javobgarlik mexanizmlarini kuchaytirish zarurligi asoslab beriladi.
Библиографические ссылки
O‘zbekiston Respublikasi Konstitutsiyasi. Yangi tahrir. 2023-yil 30-aprel.
URL: https://lex.uz/docs/-6445145
Tonelli MR. Conflict of Interest in Clinical Practice. Chest. 2007;132(2):664–670.
URL: https://journal.chestnet.org/article/S0012-3692(15)37464-X/abstract
Tibbiyot xodimlarining odob-axloq kodeksi. O‘zbekiston Respublikasi Sog‘liqni saqlash vazirining 2022-yil 24-martdagi 88-son buyrug‘i bilan tasdiqlangan.
Rasmiy manba: https://gov.uz/oz/zarafshon/news/view/129434
Kassirer JP, Angell M. Financial conflicts of interest in biomedical research. N Engl J Med. 1993;329(8):570–571.
URL: https://www.nejm.org/doi/abs/10.1056/NEJM199308193290810
Brax H, Fadlallah R, Al-Khaled L, Kahale LA, Nas H, El-Jardali F, et al. Association between physicians’ interaction with pharmaceutical companies and their clinical practices: A systematic review and meta-analysis. PLoS One. 2017;12(4).
URL: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0175493
Blumenthal D. Doctors and drug companies. N Engl J Med. 2004;351(18):1885–1890. URL: https://pubmed.ncbi.nlm.nih.gov/15509823/
Fadare JO, Oshikoya KA, Ogunleye OO, Desalu OO, Ferrario A, Enwere OO, et al. Drug promotional activities in Nigeria: Impact on the prescribing patterns and practices of medical practitioners and the implications. Hosp Pract (1995). 2018;46(2):77–87.
URL: https://pubmed.ncbi.nlm.nih.gov/29426263/
Schramm J, Andersen M, Vach K, Kragstrup J, Kampmann JP, Søndergaard J. Promotional methods used by representatives of drug companies: A prospective survey in general practice Scand J PHC. 2007;25:93–7 doi: 10.1080/02813430701339659
Şahne BS, Yeğenoğlu S, Üner MM, Wertheimer AI. Adherence of drug advertisements to the international marketing codes. Hacettepe University Journal of the Faculty of Pharmacy. 2012;32(1):53–66. URL: https://dergipark.org.tr/en/pub/hujpharm/article/639002
Khazzaka M. Pharmaceutical marketing strategies’ influence on physicians’ prescribing pattern in Lebanon: Ethics gifts, and samples BMC Health Serv Res. 2019;19(80) doi: 10.1186/s12913-019-3887-6
. Revenue of the worldwide pharmaceutical market from 2001 to 2019 (in billion US dollars) https://www.statista.com/statistics/263102/pharmaceutical-market-worldwide-revenue-since--2001/. Accessed May 15, 2020
Roy N, Madhiwalla N, Pai SA. Drug promotional practices in Mumbai: A qualitative study. Indian J Med Ethics. 2007;4(2):57–61. URL: https://pubmed.ncbi.nlm.nih.gov/18630221/
Cooper RJ, Schriger DL. The availability of references and the sponsorship of original research cited in pharmaceutical advertisements. CMAJ. 2005;172(4):487–491.
URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC548410/
Taber E, Whitesell J. Physician interaction with pharmaceutical companies: New rules and nationwide trends Northern Ohio Physician. 2009;94:1–3 https://www.tuckerellis.com/files/physician-interaction-with-parmaceutical-companies.pdf. Accessed January 31, 2019.
Randhawa GK, Singh NR, Rai J, Kaur G, Kashyap R. A critical analysis of claims and their authenticity in Indian drug promotional advertisements. Adv Med. 2015;2015:469147. URL: https://pubmed.ncbi.nlm.nih.gov/26556557/
Alam K, Shah AK, Ojha P, Palaian S, Shankar PR. Evaluation of drug promotional materials in a hospital setting in Nepal. South Med Rev. 2009;2(1):2–6. URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC3471165/
Rohra DK, Gilani AH, Memon IK, Perven G, Khan MT, Zafar H, et al. Critical evaluation of the claims made by pharmaceutical companies in drug promotional material in Pakistan. J Pharm Pharm Sci. 2006;9(1):50–59.URL: https://pubmed.ncbi.nlm.nih.gov/16849008/
Grande D, Shea JA, Armstrong K. Pharmaceutical industry gifts to physicians: Patient beliefs and trust in physicians and the health care system. J Gen Intern Med. 2012;27(3):274–279. URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC3286560/
Latten T, Westra D, Angeli F, Paulus A, Struss M, Ruwaard D. Pharmaceutical companies and healthcare providers: Going beyond the gift – an explorative review. PLoS One. 2018;13(2).
URL: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0191856
Khakhkhar T, Mehta M, Shah R, Sharma D. Evaluation of drug promotional literatures using WHO guidelines. J Pharm Negative Results. 2013;4:33–38.
DOI: https://doi.org/10.4103/0976-9234.116770
Abdulah DM, Perot KA. Pharmaceutical promotions and trustworthiness on new drug prescribing among physicians in public general hospitals. J Hosp Adm. 2019;8(6):17–23. URL: https://www.sciedupress.com/journal/index.php/jha/article/view/16133
World Health Organization. Managing conflicts of interest: a how-to guide for public pharmaceutical-sector committees in low- and middle-income countries. Geneva: World Health Organization; 2022. Licence: CC BY-NC-SA 3.0 IGO. URL: https://www.who.int/publications/i/item/9789240057982